Introduction: Antibody-drug conjugates (ADCs) offer targeted cancer therapy but face limitations like low drug-antibody ratios and poor tumor penetration. To overcome these, we developed an ADC-gold nanoparticle (GNP) platform with high drug loading, multi-drug binding, and insulin coating for enhanced uptake. Our study focuses on triple-negative breast cancer (TNBC), where current ADCs show limited efficacy. This novel approach aims to improve treatment outcomes by enhancing cellular uptake and therapeutic potency.
Learning Objectives:
understand the advantages of gold nanoparticle-based ADCs over conventional ADCs
